Royal Jelly Benefits: What the Research Actually Shows

Royal jelly does something extraordinary — for bee larvae. A female larva reared on it becomes a queen: larger, fertile, longer-lived. That is the demonstrated effect, and it is the entire engine of the substance’s reputation. In people the record is a different shape: the human trials are small and largely null, and when Europe’s food-safety authority assessed the full sweep of proposed claims — immunity, vitality, skin, menopause, cholesterol — it rejected every one, mostly on a ground worth understanding in itself: the dossiers could not establish what royal jelly consistently is. This page follows that story from the queen cell to the trial data.

Where does royal jelly’s reputation come from?

From the queen bee, and honestly from nowhere else. Royal jelly is the secretion nurse bees produce from glands in their heads; a female larva reared on it becomes a queen. Even the regulator’s factual description is bee biology — EFSA records royal jelly as “important in the sexual differentiation and longevity of the queen bee”. A 2011 Nature paper by Kamakura supplied the modern mechanism: royalactin, a royal jelly protein, driving queen development in honeybee larvae — larger bodies, developed ovaries, faster development — with similar effects in the fruit fly. That paper is the engine of every “what it does for the queen, it can do for you” pitch.

The follow-up is a lesson in how science self-corrects. The species studied were the honeybee and the fruit fly; no humans appear anywhere in the work. And even within bees, the single-molecule story did not hold: a 2016 Nature replication by Buttstedt and colleagues — titled “Royalactin is not a royal making of a queen” — experimentally excluded royalactin and the other major royal jelly proteins as single determinators of queen development, pointing instead to the larva’s overall feeding regime. Replication is the check that separates a striking result from a reliable one, and the flagship account of royal jelly’s biology failed it on its central claim. The reputation rests on developmental biology in another species, and even that biology turned out to be about the diet as a whole, not a magic ingredient. The substance itself is covered on the royal jelly page.

Plate I · IllustrationRecord

What did EFSA actually assess?

In 2011 EFSA’s expert panel assessed the royal jelly claims submitted under Article 13(1) of the EU claims regulation — twelve entries, covering “natural defence/immune system”, “metabolism”, “vascular function”, “skin health”, “tonus/vitality”, menopause, and heart, cholesterol and blood-lipid wordings. One conclusion covered them all: “a cause and effect relationship cannot be established between the consumption of royal jelly and the claimed effects”.

The interesting part is where the claims failed: before the evidence stage. To assess whether a food does something, an assessor first has to know what the food is — and the panel found royal jelly itself not sufficiently characterised. From the references provided it “was not possible to characterise royal jelly in general, nor the specific components of royal jelly mediating the functions for which the claims were made”. In the human studies submitted, the origin and composition of the royal jelly used was not even specified, and the panel noted that composition varies with seasonal and regional conditions. The question of what royal jelly does was never reached; the dossiers could not establish what it is.

What EFSA could describe is bee biology plus a composition table: a whitish, strongly acidic secretion of nurse-bee glands — water 60–70%, protein 12–15%, sugars 10–16%, lipids 3–7% — with the reported bioactive components including 10-HDA and “unidentified components with oestrogenic activity”: an identity gap sitting exactly where menopause marketing claims a mechanism.

Is any royal jelly claim authorised in Great Britain?

None — and the file repays close reading, because the sixteen rows fail in four distinct ways. The Great Britain nutrition and health claims register, maintained by the Department of Health and Social Care, is binary by design: only claims listed as authorised may be used in commercial communications. Its current edition holds sixteen royal jelly rows — seventeen entry IDs, five of them filed under the French heading “Gelée Royale” — and every one is non-authorised. The rejected wordings on file read like a supplement listing: “Strengthens body’s resistance against infections”; “Royal jelly helps promote milk secretion in breastfeeding mothers”; “Promotes a good heart functioning and a balanced level of the blood lipids”.

The four failure modes map the ways a claim can die. Most rows repeat EFSA’s characterisation finding — the food “is not sufficiently characterised for a scientific assessment of this claimed effect”. Claims worded as “tonic”, “stimulant” or “reconstituent” failed differently: the claimed effect itself was “not sufficiently defined to be able to be assessed” — too vague to test, whatever the food. Exactly one claim — protection of DNA, proteins and lipids from oxidative damage — cleared both hurdles, was assessed on its evidence, and was not substantiated. And one wording failed on a ground of its own: an anti-inflammatory claim filed as “Gelée Royale” (entry 1327) was refused because the claimed effect “is not a beneficial physiological effect as required by the Regulation”. Too variable to pin down; too vague to test; not a benefit the Regulation recognises; and where testable, not substantiated.

Fig. I · The register ledgerDiagram

Great Britain nutrition and health claims register16 royal jelly rows ·17 entry IDs· current edition

Authorised

Rejected wordings on file — three of the sixteen rows

• “Strengthens body’s resistance against infections”Non-authorised
• “Royal jelly helps promote milk secretion in breastfeeding mothers”Non-authorised
• “Promotes a good heart functioning and a balanced level of the blood lipids”Non-authorised

Failed four distinct ways

Too variable to pin downMost of the sixteen rows — EFSA’s characterisation finding“is not sufficiently characterised for a scientific assessment of this claimed effect”

Too vague to testThe “tonic”, “stimulant” and “reconstituent” wordings“not sufficiently defined to be able to be assessed”

Not a benefit the Regulation recognisesOne claim — the inflammation wording filed as “Gelée Royale”“is not a beneficial physiological effect as required by the Regulation”

Where testable, not substantiatedExactly one claim — protection of DNA, proteins and lipids from oxidative damageassessed on its evidence — not substantiated

None

16 rows· 17entriesEvery one non-authorisedAuthorised — none

What do the human trials show?

Small numbers, short durations, mostly nothing. Blood sugar is the best-measured corner, meta-analysed twice. A 2019 meta-analysis by Mahboobi and colleagues — its title is its finding: “Royal jelly does not improve markers of glycemia” — pooled five randomised trials, 205 participants for fasting glucose and 130 for HbA1c, and found no significant effect on either (fasting glucose −0.95 mg/dl, p = 0.69; HbA1c −0.32, p = 0.25). A larger 2023 meta-analysis by Bahari and colleagues pooled ten randomised trials and reached the same overall null for glycaemic indices and liver enzymes. One subgroup — trials of eight weeks or longer — showed a small fasting-glucose reduction (−4.28 mg/dl); a subgroup result inside an overall null is a hypothesis for the next trial rather than a finding, and the authors call for more primary studies.

Menopause is where the strongest popular claim meets its evidence, and the trials teach a distinction worth having. The largest trial, by Sharif and Darsareh in 2019, randomised 200 postmenopausal women aged 45–60 to 1,000 mg of royal jelly a day or placebo, double-blinded, for eight weeks, and reported that the menopausal symptom score fell significantly within the royal jelly group while the fall in the placebo group did not reach significance. That is a within-group result, and the reason trials have two arms is that within-group falls happen for many reasons — time, attention, expectation. The comparison that isolates the treatment is arm against arm, and the trial reports no significant difference between the two arms. It is the category’s best card — one short, single-centre trial with a subjective questionnaire endpoint and no large replication, published eight years after the EFSA opinion, so no regulator has weighed it. The other frequently cited trial, by Asama and colleagues in 2018, randomised 42 postmenopausal Japanese women to 800 mg enzyme-treated royal jelly or dextrin placebo for twelve weeks; exactly two questionnaire subscores reached significance — anxiety (p = 0.046) and backache and low back pain (p = 0.040). Five of its six authors were employees of the research institute of Yamada Bee Company, a royal jelly producer — a fact of the record. The GB register’s menopause entry remains non-authorised, refused before any evidence was assessed, on the characterisation ground.

How do the popular claims compare with the record?

What does the 10-HDA number actually measure?

Identity, not potency. 10-HDA — 10-hydroxy-2-decenoic acid — is royal jelly’s signature fatty acid, around 70% of its total fatty acids, and its job in the literature is authentication: a 2025 review by Gasbarri and Angelini records the 10-HDA level as the standard marker for testing royal jelly’s purity and guarding it against adulteration. The same review’s survey of the molecule’s own biological literature is preclinical throughout — in-vitro, animal and computational work, not human trials. The percentage on a label answers one question well — is this genuine royal jelly? — and a different question not at all.

Fig. II · Identity, not potencyDiagram

The 10-HDA line, as a laboratory files it

Two determinations

Motif · no laboratory, batch or result

Determination 01 · IdentityAnswered

Is this genuine royal jelly?

Marker

10-HDA — 10-hydroxy-2-decenoic acid, royal jelly’s signature fatty acid

Share

Around 70% of royal jelly’s total fatty acids

Job in the literature

Authentication — the standard marker for testing purity and guarding against adulteration

On file

A 2025 review of the molecule

Answers one question well.

Determination 02 · EffectNot answered

Does royal jelly do anything?

This panel is blankNothing is entered here. The 10-HDA percentage is an authenticity and quality marker, not a measure of effect — and the record holds no demonstrated benefit in people to enter in its place.

Evidence on the molecule

Preclinical throughout — in-vitro, animal and computational work, not human trials

And a different question not at all.

Identity, not potency.

What is the safety record?

Firmer than the efficacy record, and pointing the other way: the clearest human findings concern harm. A 1996 case series by Thien and colleagues documented seven patients who developed asthma after ingesting royal jelly, with anaphylaxis in some of them, confirmed by immunoassay as true IgE-mediated allergy, with eighteen different IgE-binding royal jelly components detected. Australia and New Zealand write the warning into food law: foods containing royal jelly must carry a prescribed statement — “This product contains royal jelly which has been reported to cause severe allergic reactions and, in rare cases, fatalities, especially in asthma and allergy sufferers.” It is the only bee product whose mandatory statement mentions fatalities.

What is a buyer actually paying for?

Identity and handling, not demonstrated effect. What can be verified about a royal jelly product is what it is — genuine or not (the 10-HDA marker exists for this), its form, its origin; our guide to buying royal jelly in the UK covers how those facts appear on a label. What the record does not contain is a demonstrated benefit in people: the regulator rejected every claim, most before the evidence stage; the pooled trial data are null; the best single trial is small, short and unreplicated; and the firmest human findings are the allergy series. That is not a verdict on the substance — it is where the evidence stops, and an unusually clean example of the gap between a reputation and a record. How the rest of the bee shelf fares under the same questions is collected in the evidence section.